How often do highly promising cancer biology discoveries translate into effective treatments?

References

1. • Contopoulos-Ioannidis D.G.
   • Ntzani E.
   • Ioannidis J.P.A.
   Translation of highly promising basic science research into clinical applications.
   Am J Med. 2003; 114: 477-484
   View in Article

   • Google Scholar
2. • Joensuu H.
   Treatment of inoperable gastrointestinal stromal tumor (GIST) with Imatinib (Glivec, Gleevec).
   Med Klin (Munich). 2002; 97: 28-30
   View in Article

   • Google Scholar
3. • Peifer C.
   • Alessi D.R.
   New anti-cancer role for PDK1 inhibitors: preventing resistance to tamoxifen.
   Biochem J. 2009; 417: e5-e7
   View in Article

   • Google Scholar
4. • Ebert A.D.
   • Ulrich U.
   • Beckmann M.W.
   • Schneider A.
   Zentralbl Gynakol. 2006; 128: 23-26
   View in Article

   • Google Scholar
5. • te Velde E.A.
   • Kusters B.
   • Maass C.
   • de Waal R.
   • Borel Rinkes I.H.M.
   Histological analysis of defective colonic healing as a result of angiostatin treatment.
   Exp Mol Pathol. 2003; 75: 119-123
   View in Article

   • Google Scholar
6. STD vaccine breakthrough. Cervarix would prevent human papilloma virus which can lead to cervical cancer; FDA approval anticipated.
   Health News Walth Mass. 2005; 11: 6-7
   View in Article

   • Google Scholar
7. • Semiglazov V.P.
   Vopr Onkol. 2001; 47: 195-199
   View in Article

   • Google Scholar
8. • Raben D.
   • Bianco C.
   • Helfrich B.
   • Weng E.
   • Ciardiello F.
   • Harari P.
   Interference with EGFR signaling: paradigm for improving radiation response in cancer treatment.
   Expert Rev Anticancer Ther. 2002; 2: 461-471
   View in Article

   • Google Scholar
9. • Harari P.M.
   • Huang S.M.
   Radiation response modification following molecular inhibition of epidermal growth factor receptor signaling.
   Semin Radiat Oncol. 2001; 11: 281-289
   View in Article

   • Google Scholar
10. • Scheithauer W.
    • Van Cutsem E.
    The role of oxaliplatin in the management of upper gastrointestinal tract malignancies.
    Colorectal Dis. 2003; 5: 36-44
    View in Article

    • Google Scholar
11. • Santiago-Schwarz F.
    Dendritic cells: friend or foe in autoimmunity?.
    Rheum Dis Clin North Am. 2004; 30: 115-134
    View in Article

    • Google Scholar
12. • Drew Y.
    • Calvert H.
    The potential of PARP inhibitors in genetic breast and ovarian cancers.
    Ann N Y Acad Sci. 2008; 1138: 136-145
    View in Article

    • Google Scholar
13. • Grégoire M.
    • Ebstein F.
    Bull Cancer (Paris). 2007; 94: 23-31
    View in Article

    • Google Scholar
14. • Irvine A.S.
    • Trinder P.K.
    • Laughton D.L.
    • et al.
    Efficient nonviral transfection of dendritic cells and their use for in vivo immunization.
    Nat Biotechnol. 2000; 18: 1273-1278
    View in Article

    • Google Scholar
15. • Walensky L.D.
    BCL-2 in the crosshairs: tipping the balance of life and death.
    Cell Death Differ. 2006; 13: 1339-1350
    View in Article

    • Google Scholar
16. • Liu X.-Y.
    • Qiu S.-B.
    • Zou W.-G.
    • et al.
    Effective gene-virotherapy for complete eradication of tumor mediated by the combination of hTRAIL (TNFSF10) and plasminogen k5.
    Mol Ther. 2005; 11: 531-541
    View in Article

    • Google Scholar
17. • Lund-Johansen F.
    • Olweus J.
    Tidsskr Den Nor Laegeforening. 1999; 119: 2510-2514
    View in Article

    • Google Scholar
18. • Lundstrom K.
    • Boulikas T.
    Viral and non-viral vectors in gene therapy: technology development and clinical trials.
    Technol Cancer Res Treat. 2003; 2: 471-486
    View in Article

    • Google Scholar